We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 293

Association not directly affected by listing on register of innovative drugs
  • Borden Ladner Gervais LLP
  • Canada
  • January 4 2012

This is an appeal from a decision of the Federal Court, upholding the decision of the Prothonotary striking the Notice of Application on the basis that the Applicant lacked standing


Disgorgement of profits allegation struck when tied to NOC regulations
  • Borden Ladner Gervais LLP
  • Canada
  • January 4 2012

This decision relates to two appeals heard together but not consolidated


Prohibition order upheld on appeal allegation as to inutility not justified
  • Borden Ladner Gervais LLP
  • Canada
  • April 23 2012

The Court of Appeal (FCA) upheld the Prohibition Order granted by the Federal Court


Amendments to pleadings allowed alleging that there should be no damages as an alternative, non-infringing process existed
  • Borden Ladner Gervais LLP
  • Canada
  • April 23 2012

The Defendants appealed an order of the Court denying leave to amend their Statements of Defence


Sound prediction applies to mechanical inventions
  • Borden Ladner Gervais LLP
  • Canada
  • September 30 2013

The Federal Court of Appeal (FCA) recently upheld the decision of the Trial Judge, holding that one claim of the patent at issue was valid and


Finding of non-infringement upheld on appeal
  • Borden Ladner Gervais LLP
  • Canada
  • February 9 2015

The Court of Appeal dismissed an appeal of a decision of the Court in a NOC proceeding finding that an allegation of non-infringement was justified


Ramipril section 8 appeal dismissed from the bench by the Supreme Court of Canada
  • Borden Ladner Gervais LLP
  • Canada
  • April 22 2015

On Monday, April 20, 2015, the Supreme Court of Canada heard the appeal of 2014 FCA 68, relating to the issue of damages under section 8 of the


Formulation patent found not to be infringed as a redacted excipient was not a “pentahydric or hexahydric alcohol”
  • Borden Ladner Gervais LLP
  • Canada
  • April 22 2015

Apotex has successfully alleged that Teva’s patent to “Stable Compositions Containing Rasagiline” will not be infringed by Apotex’s use of a


Damages portion of trial determined
  • Borden Ladner Gervais LLP
  • Canada
  • July 20 2015

This decision relates to the remedy portion of an infringement action in which the Plaintiffs were successful. That decision was upheld on appeal


Appeal in NOC Proceeding dismissed as moot
  • Borden Ladner Gervais LLP
  • Canada
  • February 9 2015

The Court of Appeal granted Teva’s motion to have an appeal from a NOC Proceeding dismissed as moot. The Respondent’s request for an oral hearing of